The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.

Mean WC showed a trend to a significant reduction at month 6 and was significantly reduced at month 12.

also in 53,322 other papers

Particularly, although FPG increased by 85.7% during the first 2 months of treatment, this transient increase did not reach statistical significance (baseline: 4.7 ± 0.8 mmol/L; 2 months: 8.4 ± 7.6 mmol/L; p 0–2 = 0.375); in fact, during the following 4 months of treatment, until 6-month follow-up, FPG non-significantly decreased by 14.9% (2 months: 8.4 ± 7.6 mmol/L; 6 months: 5.2 ± 1 mmol/L, p 2–6 = 0.297), non-significantly re-increasing by 4.7% (12 months: 5.2 ± 1.2 mmol/L; p 6–12 = 0.938) during the last 6 months of treatment in the remaining seven patients, until 12-month follow-up.

also in 111,027 other papers